Anti-PD1 antibody: a new approach to treatment of lymphomas

被引：32
|
作者：
Bachy, Emmanuel [1 ,2 ,3 ]
Coiffier, Bertrand [1 ,2 ,3 ]
机构：
[1] Hosp Civils Lyon, Dept Hematol, Lyon, France
[2] Univ Lyon 1, Dept Hematol, F-69365 Lyon, France
[3] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France
来源：
LANCET ONCOLOGY | 2014年 / 15卷 / 01期
关键词：
FOLLICULAR LYMPHOMA; T-CELLS; PD-1;
D O I：
10.1016/S1470-2045(13)70587-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：7 / 8
页数：2
相关论文
共 50 条
  • [21] Obesity enhances the response to neoadjuvant anti-PD1 therapy in oral tongue squamous cell carcinoma
    Tan, Xiyan
    Li, Guoli
    Deng, Honghao
    Xiao, Guoming
    Wang, Yaqin
    Zhang, Chenzhi
    Chen, Yanfeng
    CANCER MEDICINE, 2024, 13 (12):
  • [22] Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma
    Lepletier, Ailin
    Madore, Jason
    O'Donnell, Jake S.
    Johnston, Rebecca L.
    Li, Xian-Yang
    McDonald, Elizabeth
    Ahern, Elizabeth
    Kuchel, Anna
    Eastgate, Melissa
    Pearson, Sally-Ann
    Mallardo, Domenico
    Ascierto, Paolo A.
    Massi, Daniela
    Merelli, Barbara
    Mandala, Mario
    Wilmott, James S.
    Menzies, Alexander M.
    Leduc, Charles
    Stagg, John
    Routy, Bertrand
    Long, Georgina, V
    Scolyer, Richard A.
    Bald, Tobias
    Waddell, Nicola
    Dougall, William C.
    Teng, Michele W. L.
    Smyth, Mark J.
    CLINICAL CANCER RESEARCH, 2020, 26 (14) : 3671 - 3681
  • [23] Lenvatinib enhances antitumor immunity of anti-PD-1 antibody
    Kato, Yu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025, : 666 - 673
  • [24] Circulating immune landscape in melanoma patients undergoing anti-PD1 therapy reveals key immune features according to clinical response to treatment
    Cuevas, Eleonora Sosa
    Mouret, Stephane
    Vayssiere, Guillaume
    Kerboua, Siham
    Girard, Pauline
    Molens, Jean-Paul
    Manceau, Marc
    Charles, Julie
    Saas, Philippe
    Aspord, Caroline
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [25] PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas
    Goodman, Aaron
    Patel, Sandip P.
    Kurzrock, Razelle
    NATURE REVIEWS CLINICAL ONCOLOGY, 2017, 14 (04) : 203 - 220
  • [26] Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers
    Yang, Bo
    Liu, Tingjun
    Qu, Yang
    Liu, Hangbo
    Zheng, Song Guo
    Cheng, Bin
    Sun, Jianbo
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [27] Diagnostic and prognostic utility of PD-1 in B cell lymphomas
    Muenst, S.
    Hoeller, S.
    Willi, N.
    Dirnhofera, S.
    Tzankov, A.
    DISEASE MARKERS, 2010, 29 (01) : 47 - 53
  • [28] The XCL1-Mediated DNA Vaccine Targeting Type 1 Conventional Dendritic Cells Combined with Gemcitabine and Anti-PD1 Antibody Induces Potent Antitumor Immunity in a Mouse Lung Cancer Model
    Zhang, Ke
    Wuri, Qimuge
    Cai, Zongyu
    Qu, Xueli
    Zhang, Shiqi
    Wu, Hui
    Wu, Jiaxin
    Wang, Chu
    Yu, Xianghui
    Kong, Wei
    Zhang, Haihong
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (03)
  • [29] TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies
    Rodriguez-Ruiz, Maria E.
    Rodriguez, Inmaculada
    Mayorga, Lina
    Labiano, Tania
    Barbes, Benigno
    Etxeberria, Inaki
    Ponz-Sarvise, Mariano
    Azpilikueta, Arantza
    Bolanos, Elixabet
    Sanmamed, Miguel F.
    Berraondo, Pedro
    Caivo, Felipe A.
    Barcelos-Hoff, Mary Helen
    Perez-Gracia, Jose L.
    Melero, Ignacio
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (03) : 621 - 631
  • [30] The safety of anti PD-1 therapeutics for the treatment of melanoma
    Ramelyte, Egle
    Schindler, Sabrina A.
    Dummer, Reinhard
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (01) : 41 - 53
12345